In patients with Glycogen Storage Disease Type I, elevated uric acid is a recognised complication that can progress to hyperuricemia and recurrent gout attacks. Addressing this complication requires both dietary and pharmacological management.
GSD Type I patients with a tendency toward gout attacks present with hyperuricemia as a compounding metabolic burden. Dietary modification — specifically a low-purine diet — is a cornerstone alongside targeted urate-lowering therapy.
The protocol incorporates urate-lowering therapy directed at reducing serum uric acid levels. When conventional approaches are insufficient, a newer class of urate-lowering agent is considered. The complete sequencing, criteria, and regimen details are in the full protocol.
DOI: 10.1038/gim.2014.128
For those with a tendency toward gout attacks, a low-purine diet is prescribed in addition to allopurinol.
Newer agents, such as pegloticase, have been used in situations where the use of other agents has failed.
View source ↗